LEADING ARTICLE

Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction

R De Giorgio, G Sarnelli, R Corinaldesi, V Stanghellini

Chronic intestinal pseudo-obstruction (CIP) represents a particularly difficult clinical challenge. It is a rare and highly morbid syndrome characterised by impaired gastrointestinal propulsion together with symptoms and signs of bowel obstruction in the absence of any lesions occluding the gut lumen. CIP can be classified as either "secondary" to a wide array of recognised pathological conditions or "idiopathic" (CIIP). This review will focus on CIIP, and specifically on the underlying pathological abnormalities. Combined clinical and histopathological studies are needed to highlight new perspectives in the understanding and management of chronic intestinal pseudo-obstruction.

SUMMARY
The histopathology of chronic intestinal pseudo-obstruction has been frequently reported as a frustrating experience by gastrointestinal pathologists. Renewed interest in gut neuromuscular pathology has been fuelled by the availability of full thickness biopsies obtained with minimally invasive surgical techniques, improvement in tissue preservation, and refinement of a number of morphofunctional techniques. Pathological abnormalities underlying chronic idiopathic intestinal pseudo-obstruction can be classified into three major entities: neuropathies, "mesenchymopathies" (that is, changes in interstitial cells of Cajal network), and myopathies. Inflammatory/immune mediated neuropathies are characterised by either a predominant T cell (CD4 and CD8 lymphocytes) or eosinophilic infiltrate within the myenteric plexus. Other forms of neuropathies are characterised by loss of neurones together with evidence of neurodegenerative aspects in the absence of an identifiable inflammatory response. Abnormalities of interstitial cells of Cajal and smooth muscle cells may also contribute to gut dysmotility. Combined clinical and histopathological studies will open new perspectives in the understanding and management of chronic intestinal pseudo-obstruction.

CHRONIC INTESTINAL PSEUDO-OBSTURATION: A GENERAL OVERVIEW ON A RARE DISEASE
Digestive motility is a highly coordinated process which enables mixing, absorption, and propulsion of the ingesta through the gastrointestinal tract up to expulsion of residues. This function depends on smooth muscle contractility and the related pacemaker activity evoked by the interstitial cells of Cajal (ICCs), both finely tuned by intrinsic (that is, the enteric nervous system (ENS)) and extrinsic (that is, sympathetic and parasympathetic) nerves.1 2 Disturbances in digestive motility can occur as a result of a variety of abnormalities affecting each of these elements (alone or in combination) involved in the physiology of gut motor function.3 7

"Intestinal pseudo-obstruction represents a particularly difficult clinical challenge"

Intestinal pseudo-obstruction represents a particularly difficult clinical challenge. It is a rare and highly morbid syndrome characterised by impaired gastrointestinal propulsion together with symptoms and signs of bowel obstruction in the absence of any lesions occluding the gut lumen.3-5 Pseudo-obstructive syndromes may be either acute (due to abdominal surgery, retroperitoneal haemorrhage, spinal or pelvic trauma, myocardial infarction, or hypokalaemia) or, more commonly, chronic. The latter form (that is, chronic intestinal pseudo-obstruction (CIP)) is an important cause of chronic functional intestinal failure. CIP can be further classified as either "secondary" to a wide array of recognised pathological conditions1-3 or "idiopathic" (CIIP). Although familial forms with autosomal dominant or recessive modes of inheritance have been reported,3-4 most cases of CIP appear to be unrelated to familial clusters and therefore are referred to as sporadic forms. This review will focus on CIIP, and specifically on the underlying pathological abnormalities.

CLINICAL AND DIAGNOSTIC FEATURES
CIIP patients present with recurrent episodes of abdominal pain, nausea and/or vomiting, and distension and/or bloating mimicking a mechanical sub-occlusion.5-7 Diarrhoea and steatorrhoea may occur as a result of bacterial overgrowth of the small intestine. Dysphagia is present in a low percentage of patients with CIIP although it is relatively frequent in those affected by pseudo-obstruction secondary to progressive systemic sclerosis. Nausea, vomiting, and weight loss are

Abbreviations: ANNA-1, antineuronal nuclear antibodies; BCL-2, B cell lymphoma 2; CIP, chronic intestinal pseudo-obstruction; CIIP, chronic intestinal idiopathic pseudo-obstruction; ICC, interstitial cells of Cajal; ENS, enteric nervous system
predominant symptoms when gut dysfunction affects the upper gastrointestinal tract whereas diffuse abdominal pain, severe distension, and constipation are suggestive of an impairment primarily affecting the distal gut. Between sub-occlusive episodes, patients may be asymptomatic or complain of symptoms of variable intensity. The onset of CIIP is generally insidious (that is, gastrointestinal symptoms of increasing severity may precede the first sub-occlusive episode by many years) or, less frequently, it is abrupt (that is, presenting with a sub-occlusive episode)." Repeated laparotomies, often preceding the correct diagnosis, represent a common finding in the clinical history of these patients.

The diagnosis of CIIP is mainly clinical and confirmed by endoscopic or radiological exclusion of mechanical causes as well as by evidence of air-fluid levels in distended bowel loops. Standard or ambulatory intestinal manometry, although not mandatory in the diagnostic workup of CIIP, may help in differentiating mechanical from functional forms of sub-occlusion. This test also provides information on the origin of the underlying dysmotility, referred to as myogenic or neurogenic depending on the putative abnormality of sub-occlusion. This test also provides information on the origin of the underlying dysmotility, referred to as myogenic or neurogenic depending on the putative abnormality of sub-occlusion.

"The diagnosis of CIIP is mainly clinical and confirmed by endoscopic or radiological exclusion of mechanical causes as well as by evidence of air-fluid levels in distended bowel loops."

However, during the 1980s, Krishnamurthy and Schuffler proposed a classification of enteric neuromuscular abnormalities in patients with severe dysmotility, based mainly on histochemical assessment. Although accurately detailed, this classification progressively lost its intrinsic value as a result of the overwhelming knowledge emerging from basic studies on enteric neuromuscular structure and function (for review see De Giorgio and colleagues). Based on tissue examination, CIIP can be classified into three major forms: (a) inflammatory neuropathies in which a significant inflammatory/immune response is identified within enteric ganglia and/or nerve processes; and (b) degenerative neuropathies characterised by evidence of neurodegenerative aspects in the absence of an identifiable inflammatory response.

"Damage to the functional and/or structural integrity of the ENS plays a major role in gut dysmotility."

"Damage to the functional and/or structural integrity of the ENS plays a major role in gut dysmotility."

Inflammatory neuropathies are characterised by a dense infiltrate of lymphocytes and plasma cells involving either of the two major ganglionated plexuses, although mainly the myenteric plexus (that is, myenteric ganglionitis) and axons of the ENS. Usually, cases of myenteric ganglionitis are secondary to several diseases, including paraneoplastic (for example, small cell carcinoma, carcinoid, neuroblastoma, and thymoma), infectious (for example, Chagas' disease), neurological (for example, encephalomyeloneuropathy), connective tissue (for example, scleroderma), and inflammatory bowel disorders (for review see De Giorgio and colleagues). Nevertheless, some cases may be idiopathic in origin. Immunohistopathological analysis shows an immune infiltrate composed of predominant CD4 (T helper) and CD8 (T suppressor) lymphocytes (fig 1) which can be identified in idiopathic and secondary forms of myenteric ganglionitis. Lymphocytic myenteric ganglionitis often results from an inflammatory response characterised by antineuronal antibodies, namely antinuclear neuronal antibodies (ANNA-1) or anti-Hu (from the name of the molecular target recognised by these autoantibodies). Detection of ANNA-1/anti-Hu antibodies in the serum of patients with idiopathic myenteric ganglionitis is useful for diagnosis and helps to establish the rationale for appropriate immunosuppressive treatment. By contrast, recent data showed a predominant eosinophilic infiltrate in the myenteric plexus of paediatric cases of CIIP which does not appear to be associated with overt neurodegeneration.

Degenerative non-inflammatory neuropathies may occur as a result of endogenous and/or exogenous noxae leading to damage and loss of enteric neurones. Typical neuropathological findings include marked reduction of intramural (especially myenteric) neurones associated with swollen cell bodies and processes, fragmentation and loss of axons, and...
neurotransmitter disorders of the ENS in colonic inertia,7 muscularis propria. Although several studies have focused on increased number of Schwann cells and hypertrophy of the enlarged with thick clubbed processes and associated with an apoptosis in CIIP tissues.22

Figure 1 Representative photomicrograph illustrating a case of idiopathic lymphocytic myenteric ganglionitis. The immune infiltrate is localised within the myenteric plexus of the small bowel of a patient with chronic intestinal idiopathic pseudo-obstruction. The positive immunolabelling (light red/pink colour) identifies CD8 T lymphocytes (A). The inset selected (B) is a higher magnification of (A) showing the close proximity between CD8 positive lymphocytes and myenteric neurones (arrows). Alkaline phosphatase antialkaline phosphatase immunohistochemical technique. Original magnifications: 80×, A; 160×, B.

proliferation of glial cells.6–7 Remaining neurones may be enlarged with thick clubbed processes and associated with an increased number of Schwann cells and hypertrophy of the muscularis propria. Although several studies have focused on neurotransmitter disorders of the ENS in colonic inertia, only a few have been performed in patients with degenerative neuropathy underlying CIIP.

“Enteric neurones of patients with CIIP display reduced expression of the protein encoded by BCL-2 (B cell lymphoma-2), a gene related to one of the intracellular pathways leading to programmed cell death”

Possible pathogenetic mechanisms involved in central nervous system neurodegenerative disorders have been assumed to occur in enteric neuropathies due to the high degree of similarity shared by central and enteric neurones.13 Neurodegenerative mechanisms include altered calcium signalling, mitochondrial dysfunction, and production of free radicals.20 Preliminary data have demonstrated that enteric neurones of patients with CIIP display reduced expression of the protein encoded by BCL-2 (B cell lymphoma-2), a gene related to one of the intracellular pathways leading to programmed cell death,11 and this decreased BCL-2 expression was associated with enhanced activation of neuronal programmed cell death/apoptosis in CIIP tissues.21

ICC abnormalities
Alterations in the ICC network have been reported in patients with CIIP.21–25 Electron microscopy and/or KIT immunolabelling combined with confocal microscopy and image analysis demonstrated a quantitative decrease in ICCs along with structural abnormalities such as loss of processes and damaged intracellular cytoskeleton and organelles. The evidence of significant changes in the ICC enteric network further illustrates the critical role played by these non-neuronal cells in regulating gut motility.26–27

Myopathies
Histopathological analysis of tissue obtained from patients with CIIP due to an underlying primary visceral myopathy showed smooth muscle fibrosis and marked vacuolisation of the circular and longitudinal layers of the intestinal wall, although these changes may predominantly exist in only one layer.7 11 Similar to that described for neuropathies, refinement of morphofunctional techniques (for example, immunohistochemistry and electron microscopy) has significantly improved our understanding of enteric myopathies.9 In 1992, Smith and colleagues29 described the first case of a specific protein defect with no underlying structural abnormality demonstrable by either light or electron microscopy. In this issue of Gut, Knowles and colleagues report the results of a multicentre study on a large series of well characterised CIIP patients (studied by small bowel manometry and laparoscopic biopsy) (see page 1583). They showed a selective decrease or absence of α-actin staining in the circular muscle of the jejunum in approximately 25% (n = 28) of patients with CIIP. Based on these findings, the authors suggested that changes in α-actin staining could be used as a biological marker of CIIP.

“Refinement of morphofunctional techniques has significantly improved our understanding of enteric myopathies”

Although interesting, these results should be interpreted with caution. Firstly, this study showed that α-actin may undergo complex post-translational processing as its expression also appears to be deficient in the control ileum. This raises two questions: one is about the risk of false positive results due to inappropriate sampling during surgery and the other pertains to the specificity of α-actin immunoreactivity. Secondly, some of the cases with α-actin abnormalities were defined as neurogenic forms of CIIP, thus providing a conceptual gap on the clinical correlate of α-actin changes. Thirdly, CIIP is a heterogeneous syndrome and most histopathological features (that is, nerve, muscle, and ICC abnormalities) may co-exist at the tissue level and contribute synergistically to severe dysmotility. Further studies based on α-actin assessment with western blotting (to identify conformational changes in the α-actin molecule) and/or polymerase chain reaction (to identify possible α-actin altered expression) are needed to clarify the meaning of abnormal α-actin staining and its association with CIIP.

FUTURE PERSPECTIVES
Although the pathology of chronic intestinal pseudo-obstruction requires further study before an effective nosology can be definitely proposed, combined clinical and histopathological studies should be encouraged in order to provide the basic framework for standardising the histological evaluation of tissue obtained from patients with CIIP. The growing knowledge in neuropathies, myopathies, and ICC network abnormalities is fundamental for generating new therapeutic approaches. Progress in histopathology will likely help in taking the term “idiopathic” out of intestinal pseudo-obstruction syndrome.

ACKNOWLEDGEMENTS
The original work of the authors was supported by a grant from the Italian Ministry of Education, University and Research (COFIN 2003 to R De G and VS) and funds from the University of Bologna to R De G, RC, and VS. Professor VS was a recipient of a Janssen Foundation Educational grant.

Authors’ affiliations
R De Giorgio, R Corinaldesi, V Stanghellini, Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
G Sarnelli, Gastroenterology Unit, Department of Clinical and Experimental Medicine, University “Federico II”, Naples, Italy

References
1992, Smith and colleagues29 described the first case of a specific protein defect with no underlying structural abnormality demonstrable by either light or electron microscopy. In this issue of Gut, Knowles and colleagues report the results of a multicentre study on a large series of well characterised CIIP patients (studied by small bowel manometry and laparoscopic biopsy) (see page 1583). They showed a selective decrease or absence of α-actin staining in the circular muscle of the jejunum in approximately 25% (n = 28) of patients with CIIP. Based on these findings, the authors suggested that changes in α-actin staining could be used as a biological marker of CIIP.

“Refinement of morphofunctional techniques has significantly improved our understanding of enteric myopathies”

Although interesting, these results should be interpreted with caution. Firstly, this study showed that α-actin may undergo complex post-translational processing as its expression also appears to be deficient in the control ileum. This raises two questions: one is about the risk of false positive results due to inappropriate sampling during surgery and the other pertains to the specificity of α-actin immunoreactivity. Secondly, some of the cases with α-actin abnormalities were defined as neurogenic forms of CIIP, thus providing a conceptual gap on the clinical correlate of α-actin changes. Thirdly, CIIP is a heterogeneous syndrome and most histopathological features (that is, nerve, muscle, and ICC abnormalities) may co-exist at the tissue level and contribute synergistically to severe dysmotility. Further studies based on α-actin assessment with western blotting (to identify conformational changes in the α-actin molecule) and/or polymerase chain reaction (to identify possible α-actin altered expression) are needed to clarify the meaning of abnormal α-actin staining and its association with CIIP.

FUTURE PERSPECTIVES
Although the pathology of chronic intestinal pseudo-obstruction requires further study before an effective nosology can be definitely proposed, combined clinical and histopathological studies should be encouraged in order to provide the basic framework for standardising the histological evaluation of tissue obtained from patients with CIIP. The growing knowledge in neuropathies, myopathies, and ICC network abnormalities is fundamental for generating new therapeutic approaches. Progress in histopathology will likely help in taking the term “idiopathic” out of intestinal pseudo-obstruction syndrome.

ACKNOWLEDGEMENTS
The original work of the authors was supported by a grant from the Italian Ministry of Education, University and Research (COFIN 2003 to R De G and VS) and funds from the University of Bologna to R De G, RC, and VS. Professor VS was a recipient of a Janssen Foundation Educational grant.

Authors’ affiliations
R De Giorgio, R Corinaldesi, V Stanghellini, Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
G Sarnelli, Gastroenterology Unit, Department of Clinical and Experimental Medicine, University “Federico II”, Naples, Italy
What is the diagnosis?

dilatation of the colon without mechanical obstruction and bowel obstructive symptoms. Abdominal radiographs showed formed. Haematuria resolved but the patient experienced transcatheter arterial embolisation of the lesion was performed. Rhagic changes of a large renal angiomyolipoma. Selective Clinical presentation

Unusual complication of tuberous sclerosis complex

Clinical presentation

A 39 year old man with a known history of tuberous sclerosis complex (TSC) presented with haematuria due to haemorrhagic changes of a large renal angiomyolipoma. Selective transcatheter arterial embolisation of the lesion was performed. Haematuria resolved but the patient experienced postembolisation syndrome with fever, and presented with bowel obstructive symptoms. Abdominal radiographs showed marked dilatation of the colon. An acute colonic pseudo-obstruction (Ogilvie’s syndrome) was suspected and colonoscopic decompression was performed. Colonoscopy showed dilatation of the colon without mechanical obstruction and multiple sessile polyps localised in the rectum (fig 1A). One polyp was biopsied and fig 1B shows the microscopic features.

Question

What is the diagnosis?

See page 1565 for answer

This case is submitted by:

D Chatelain, H Sevestre
Department of Pathology, CHU Amiens, Amiens Cedex 01, France

H Zaher, M Flamant, F Brazier, G Geslin, J-L Dupas
Department of Gastroenterology, CHU Amiens, Amiens Cedex 01, France

J-M Regimbeau
Department of Surgery, CHU Amiens, Amiens Cedex 01, France

Correspondence to: D Chatelain, Service d’Anatomie Pathologique, CHU Amiens, Place Victor Pauchet, 80054 Amiens Cedex 01, France; Chatelain.denis@chu-amiens.fr

doi: 10.1136/gut.2003.037713

REFERENCES

Unusual complication of tuberous sclerosis complex

D Chatelain, H Sevestre, H Zaher, M Flamant, F Brazier, G Geslin, J-L Dupas and J-M Regimbeau

*Gut* 2004 53: 1552
doi: 10.1136/gut.2003.037713

Updated information and services can be found at:
http://gut.bmj.com/content/53/11/1552

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/